Consulta Pública: Guías de DDHH para Compañías Farmacéuticas en relación al Acceso a Medicamentos

Paul Hunt, el Relator de las Naciones Unidas sobre el Derecho a la Salud ha publicado un borrador de documento en consulta pública. Las Guías fueron lanzadas el 19 de Septiembre de 2007, y se puede enviar comentarios hasta el 31 de Diciembre de 2007.

Human Rights Guidelines for Pharmaceutical Companies in relation to Access to Medicines, draft for consultation

Bases: según Hunt los puntos clave para esdte tipo de análisis son los siguientes

    1. Identification of the relevant national and international human rights laws, norms and standards.
    2. Recognition that the right to health is subject to resource constraints and progressive realisation, requiring the identification of indicators and benchmarks to measure progress (or the lack of it) over time.
    3. Nonetheless, recognition that some obligations arising from the right to health are subject to neither resource constraints nor progressive realisation, but are of immediate effect e.g. the obligation to avoid de jure and de facto discrimination.
    4. Recognition that the right to health includes freedoms (e.g. freedom from non-consensual treatment and non-consensual participation in clinical trials) and entitlements (e.g. to a system of health care and protection). For the most part, freedoms do not have budgetary implications, while entitlements do.
    5. All health services, goods and facilities shall be available, accessible, acceptable, of good quality and safe. Accessible has a number of dimensions, such as affordable (i.e. financially accessible) and transparent (i.e. accessible health-related information).
    6. States have duties to respect, protect and fulfil the right to the highest attainable standard of health.
    7. Because of their crucial importance, the analytical framework demands that special attention is given to issues of non-discrimination, equality and vulnerability.
    8. The right to health requires that there is an opportunity for the active and informed participation of individuals and communities in decision-making that bears upon their health.
    9. Developing countries have a responsibility to seek international assistance and cooperation, while developed States have some responsibilities towards the realisation of the right to health in developing countries.
    10. The right to health requires that there are effective, transparent and accessible monitoring and accountability mechanisms available at the national and international levels.

 

Ver en: http://www2.essex.ac.uk/human_rights_centre/rth/

Anuncios

Una respuesta to “Consulta Pública: Guías de DDHH para Compañías Farmacéuticas en relación al Acceso a Medicamentos”

  1. Alexwebmaster Says:

    Hello webmaster
    I would like to share with you a link to your site
    write me here preonrelt@mail.ru

Responder

Introduce tus datos o haz clic en un icono para iniciar sesión:

Logo de WordPress.com

Estás comentando usando tu cuenta de WordPress.com. Cerrar sesión / Cambiar )

Imagen de Twitter

Estás comentando usando tu cuenta de Twitter. Cerrar sesión / Cambiar )

Foto de Facebook

Estás comentando usando tu cuenta de Facebook. Cerrar sesión / Cambiar )

Google+ photo

Estás comentando usando tu cuenta de Google+. Cerrar sesión / Cambiar )

Conectando a %s


A %d blogueros les gusta esto: